

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

Different distribution of antimicrobial resistance genes and virulence profiles of *Staphylococcus aureus* strains isolated from clinical mastitis in six countries

This is the author's manuscript

Original Citation:

Availability:

This version is available <http://hdl.handle.net/2318/1733855> since 2020-03-16T14:58:25Z

Published version:

DOI:10.3168/jds.2019-17141

Terms of use:

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

Different distribution of antimicrobial resistance genes and virulence profiles of *Staphylococcus aureus* strains isolated from clinical mastitis in six countries

J. Dairy Sci. 103:3431–3446 <https://doi.org/10.3168/jds.2019-17141> © American Dairy Science Association®, 2020.

V. Monistero,¹ * A. Barberio,² * F. Biscarini,³ † P. Cremonesi,³ B. Castiglioni,³ H. U. Graber,⁴ E. Bottini,⁵ A. Ceballos-Marquez,⁶ V. Kroemker,⁷ I. M. Petzer,⁸ C. Pollera,¹ C. Santisteban,⁹ M. Veiga Dos Santos,¹⁰ V. Bronzo,¹ R. Piccinini,¹ G. Re,¹¹ M. Cocchi,¹² and P. Moroni^{1,9‡}

¹ Università degli Studi di Milano, Dipartimento di Medicina Veterinaria, Italy, 20133 ² Istituto Zooprofilattico Sperimentale delle Venezie, Sezione Territoriale di Padova, Legnaro (PD), Italy, 3020 ³ Institute of Agricultural Biology and Biotechnology, National Research Council, Lodi, Italy, 26900 ⁴ Agroscope, Research Division, Food Microbial Systems, Bern, Switzerland, 3003 ⁵ Laboratorio de Microbiología Clínica y Experimental, Departamento de Sanidad Animal y Medicina Preventiva SAMP/CIVENTAN, Becaria CONICET, Facultad de Ciencias Veterinarias, Universidad Nacional del Centro de la Provincia de Buenos Aires (FCV, UNCPBA), Paraje Arroyo Seco S/N, Campus Universitario, CP 7000 Tandil, Argentina ⁶ Laboratorio de Calidad de Leche y Epidemiología Veterinaria (Grupo CLEV), Universidad de 6 Caldas, Manizales, 170003, Colombia ⁷ Bioprocess Engineering-Faculty II, Microbiology, University of Applied Sciences and Arts, 30453 Hannover, Germany ⁸ Faculty of Veterinary Science, Onderstepoort, University of Pretoria, 0110, South Africa ⁹ Quality Milk Production Services, Animal Health Diagnostic Center, Cornell University, Ithaca, NY 14850 ¹⁰ Department of Animal Nutrition and Production, School of Veterinary Medicine and Animal Sciences, Pirassununga-SP 13635900, Brazil ¹¹ Università degli Studi di Torino, Dipartimento di Scienze Veterinarie, Turin, Italy, 10085 ¹² Istituto Zooprofilattico Sperimentale delle Venezie, Sezione Territoriale di Udine, Basaldella di Campofornido (UD), Italy, 33030

ABSTRACT

Staphylococcus aureus is recognized worldwide as one of the main contagious mastitis agents in cattle and can express a set of antimicrobial resistance genes and virulence-associated genes that explain the wide range of outcomes of intramammary infections. *Staphylococcus aureus* strains are heterogeneous: their different resistance and virulence patterns, associated with host-level factors and treatment factors, are related to the severity of infection. The aim of this study was to determine phenotypic antibiotic susceptibility, occurrence of selected antimicrobial resistance genes and other virulence genes in 93 *S. aureus* strains isolated from clinical mastitis in 6 countries: Argentina, Brazil, Germany, Italy, the United States (New York State), and South Africa. These isolates were tested against a total of 16 drugs (amoxicillin-clavulanate, ampicillin, cefazolin, cefoperazone, cefquinome, enrofloxacin, erythromycin, gentamicin, kanamycin, lincomycin, oxacillin, penicillin, rifampin, spiramycin, sulfamethoxazole/trimethoprim, tylosin) by minimum inhibitory concentration (MIC) assay, and examined for the presence of 6 antibiotic-resistance genes (*bla_Z*, *mecA*, *mecC*, *ermA*, *ermB*, *ermC*) and 6 virulence-associated genes (*scn*, *chp*, *sak*, *hla*, *hlb*, *sea*) via PCR analysis. The phenotypic results of this study revealed the presence of 19.4% penicillin-resistant strains, whereas 22.6% of the strains were classified as having resistance (5.4%) or intermediate resistance (17.2%) to erythromycin. Most (96.8%) of the isolates were inhibited by cephalosporins, and all were susceptible to amoxicillin-clavulanate. Two strains (1 from Germany, 1 from Italy) were resistant to oxacillin and were positive for *mecA*. Among the other antimicrobial resistance genes, the most frequently detected was *bla_Z*

(46.2%), and 32.3% of the isolates were positive for erm genes: ermC (21.5%) and ermB (10.8%). The most prevalent virulence gene was hla (100%), followed by hlb (84.9%) and sea (65.6%). These results show a low prevalence of antibiotic multidrug resistance in *S. aureus* isolates, even if the detection of selected antimicrobial resistance genes did not always correspond with the occurrence of phenotypic antibiotic resistance; the immune evasion cluster gene prevalence was quite low in the samples analyzed.

Key words: dairy cow, mastitis, *Staphylococcus aureus*, virulence gene, antimicrobial resistance gene, MIC

INTRODUCTION

Mastitis is a common disease of dairy cows and a major concern for the dairy industry because of economic losses due to decreased animal health and increased antibiotics usage (Heikkilä et al., 2018; Gussmann et al., 2019). *Staphylococcus aureus* is one of the major agents of contagious mastitis, responsible for mainly subclinical but also clinical infections in cattle worldwide (Barkema et al., 2006). This pathogen, in combination with both the bovine host and environmental factors, is characterized by low cure rates compared with other mastitis pathogens because of its capability to acquire antibiotic resistance and produce a wide array of virulence factors (Malinowski et al., 2002; Moroni et al., 2006; Sakwinska et al., 2011; Gao et al., 2012). Higher parity is associated with a lower probability of cure, which is lower also in older cows with high SCC and in cows infected in hindquarters during early and mid-lactation (Sol et al., 1997). Although *S. aureus* responds poorly to treatment with many different antimicrobial agents, antibiotic therapy still plays a significant role in the prevention and cure of bovine staphylococcal mastitis. The infection of cows with increasingly antibiotic-resistant strains can cause several therapeutic problems and is one of the main reasons for monitoring drug resistance (Pol and Ruegg, 2007; USDA, 2007; Saini et al., 2012a). The measurement of *S. aureus* antimicrobial resistance using phenotypic susceptibility tests, such as disk diffusion or MIC assay, is essential in order to select the most appropriate and efficient therapy (Walker, 2006). These methods can be combined with molecular analysis, as phenotypic *S. aureus* resistance to the most commonly used antimicrobials is related to the expression of antibiotic-resistance genes (Cockerill, 1999). The genes associated with resistance to β -lactams are often detected in *S. aureus* isolates from bovine milk samples, because β -lactams have been widely used to prevent and treat mastitis cases for several decades (Saini et al., 2012a; Saini et al., 2012b). Among the genes encoding β -lactamase, blaZ is responsible for resistance to penicillin (Olsen et al., 2006), whereas the mecA (Sawant et al., 2009) and mecC (Paterson et al., 2014) genes confer resistance to methicillin, a semisynthetic penicillinase-resistant penicillin. Another concern is the emergence of erythromycin resistance regulated by the ermA, ermB, and ermC genes encoding different ribosomal methylases (Gatermann et al., 2007). In addition to antibiotic-resistance genes, *S. aureus* strains can harbor virulence genes in different combinations, thereby expressing factors used to attach, colonize, invade, and infect the host, which contribute largely to the establishment and severity of bovine mastitis (Jarraud et al., 2002). Many *S. aureus* virulence factors can be described as toxins (Otto, 2014). Among them, the hemolysins are cytolytic toxins able to lyse different types of cells. *Staphylococcus aureus* isolates from bovine mastitis, in particular, show a high level of expression of α -toxin (hla), exhibiting dermonecrotic and neurotoxic effects on a wide range of mammalian cells (Berube and Bubeck Wardenburg, 2013). β -Toxin (hlb) is a sphingomyelinase that damages cell membranes rich in this lipid; it is produced abundantly by isolates of animal origin (Clarke and Foster, 2006), as it increases the adherence of *S. aureus* to bovine mammary epithelial cells (Magro et al., 2017). *Staphylococcus aureus* can also produce a wide array of enterotoxins (from SEA to SEQ): SEA, in particular, is able to promote the ability of *S. aureus* to evade host immune defenses by negatively affecting the activity of

neutrophils (Xu et al., 2014). The gene for enterotoxin A (sea) belongs to the immune evasion cluster (IEC), which also includes scn, chp, sak, and other enterotoxin genes (sep, sek, or seq; Cuny et al., 2015). This cluster can interfere with host immunity and is common in methicillin-resistant *S. aureus* (MRSA) strains isolated from humans (McCarthy and Lindsay, 2013); in animals, it was previously detected in MRSA isolates from horses (Cuny et al., 2015). Because *S. aureus* virulence and antimicrobial resistance profiles are associated with specific genotypes (Fournier et al., 2008), a greater understanding of the epidemiology of *S. aureus* genotypes in dairy herds may help monitor the emergence of antimicrobial-resistant strains associated with their virulence characteristics. The aim of this study was to determine (1) the phenotypic antimicrobial susceptibility and (2) the prevalence of selected antimicrobial resistance genes and other virulence genes in 93 *S. aureus* isolates from clinical mastitis milk samples collected in 6 different countries; all these isolates were previously genotyped by RS-PCR (Monistero et al., 2018).

MATERIALS AND METHODS

Herd and Isolate Enrollment Criteria

Ninety-three *S. aureus* isolates from single-quarter (Q) and composite (C) milk samples of cows with clinical mastitis were collected between 2012 and 2017 from 76 farms in 6 countries: Argentina, Brazil, Germany, Italy, the United States (New York State), and South Africa (Table 1). Farms enrolled in the present and prior study (Monistero et al., 2018) were required to have a minimum of 120 lactating cows, to participate in monthly DHI testing or to use monthly California Mastitis Test for all lactating animals, to use a milking routine including fore-stripping of quarters for detection of mastitis, and to have a farm survey once a year by sending quarter or composite milk samples to the reference laboratory. The isolates were selected based on a non-probability convenience sample, and only isolates from clinical mastitis were selected for this study. Considering a within-herd mastitis prevalence of 20%, of which 10 to 15% were clinical cases, this yielded 2 to 4 isolates per farm.

Sample Collection

Milk samples were collected by farm personnel trained to detect mastitis cases. After disinfection of teat ends and discarding the first streams of foremilk, milk was collected in 10-mL sterile vials, labeled with cow number and quarter. Clinical mastitis was defined as visibly abnormal milk from a mammary quarter (Wenz et al., 2001; Ruegg, 2011). Milk samples were stored at 4°C and shipped to their respective laboratories. Ten microliters of each sample were plated on blood agar plates, and bacterial cultures were evaluated after 24 h of aerobic incubation at 37°C. *Staphylococcus aureus* colonies were round, smooth, substantial, opaque, characterized by hemolysis, and positive in the tube coagulase test (Cookson, 1997). One colony of each *S. aureus* isolate was subcultured and stored at -20°C. The isolates were shipped frozen on either dry ice or wet ice, depending on the distance, to the Department of Veterinary Medicine (University of Milan, Italy). Upon arrival, isolates were stored at -20°C.

Antimicrobial Susceptibility

Testing The MIC of 16 antimicrobials were determined for 93 *S. aureus* isolates, using the broth dilution test according to the procedure described in Clinical and Laboratory Standards Institute (CLSI) guidelines VET01-A4 (CLSI, 2013). The MIC were performed with a customized commercial microdilution MIC system (Micronaut-S MIC Mastitis, Merlin Diagnostika, GmbH, Bornheim, Germany) used for routine laboratory testing of mastitis isolates. Results were interpreted using

available CLSI resistance breakpoints according to VET01-S2 guidelines (CLSI, 2013) or other breakpoints reported in the literature if CLSI standards were not established. If breakpoints were differentiated for host species, cattle breakpoints were selected. The CLSI breakpoints were used for the following antimicrobials: amoxicillin-clavulanate, ampicillin, cefazolin, enrofloxacin, erythromycin, gentamicin, oxacillin, penicillin, rifampin, and sulfamethoxazole/trimethoprim. The breakpoints standardized by Société française de microbiologie (2018) were used for lincomycin, kanamycin, and spiramycin; literature references were used for cefoperazone (Feßler et al., 2012), cefquinome (Lang et al., 2002), and tylosin (Simjee et al, 2011). Furthermore, the MIC inhibiting the growth of 90% of the isolates (MIC₉₀) was calculated for each antimicrobial. The MIC plates reading was performed manually, and the last concentration of antimicrobial that did not show turbidity or a deposit of cells at the bottom of the well was recorded. The MIC value of each isolate, expressed as micrograms per milliliter, was defined as the lowest concentration of the antimicrobial agent that completely inhibited the growth after the incubation period. *Staphylococcus aureus* ATCC 29213 was used as a quality-control strain in each MIC batch, and a double negative control was used for each plate. The antimicrobials used on the plate were selected based on their activity against mastitis pathogens and on their registrations for dairy cattle. Ceftiofur was not included in the plate, because this drug is not approved for mastitis treatment in Europe, as opposed to the United States and Canada. Considering that third-generation cephalosporins are generally not advised for *S. aureus* treatment, specific testing for this antimicrobial was not performed in the present study

β-Lactamase Detection

Phenotypic β-lactamase activity was determined using the nitrocefin-based test (nitrocefin disks, SigmaAldrich, St. Louis, MO), performed according to the manufacturer's instructions and to VET08 guidelines (CLSI, 2018). *Staphylococcus aureus* ATCC 29213 and *S. aureus* ATCC 25923 were used as positive and negative controls, respectively.

Molecular Analysis DNA Extraction.

DNA was extracted from the isolates following the protocol described by Cremonesi and coworkers (2006). After the measurement of its amount and quality using a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE), DNA was stored at -20°C.

Molecular Characterization.

The DNA extracted from the 93 isolates was amplified via specific PCR analysis to determine the occurrence of 6 antibiotic-resistance genes (*bla_Z*, *mecA*, *mecC*, *ermA*, *ermB*, *ermC*), the hemolysins (*hla* and *hly*) and the IEC genes (*chp*, *sak*, *scn*, and *sea*). All these genes were investigated using primers and protocols described in literature (Table 2). Each PCR reaction contained a total of 12.5 μL of Phusion High-Fidelity Master Mix 2× (Thermo Fisher Scientific, Waltham, MA) for detection of *bla_Z*, *ermA*, and *hla* or 12.5 μL of PCR Master Mix 2× (Thermo Fisher Scientific) to investigate the other genes considered; 0.2 μL of each primer (100 μM) were added to 2 μL of genomic DNA (5 ng/μL). As positive controls, *S. aureus* reference strains (ATCC 19040, ATCC 19041, ATCC 19048, ATCC 700699, or *S. aureus* isolates from the collection of IZSLER, previously analyzed by molecular tests) were used in each PCR assay (Table 3). All amplified PCR fragments were visualized on 2% agarose gel electrophoresis (GellyPhor, Euroclone, Milan, Italy), stained with ethidium bromide (0.05 mg/mL; Sigma-Aldrich), and visualized under UV transilluminator (BioView Ltd., Nes Ziona, Israel). A 100-bp DNA ladder (Finnzymes, Espoo, Finland) was included in each gel.

RESULTS

Antimicrobial Profiling and Virulence Profiling The 93 *S. aureus* strains analyzed in this study were identified with the same identification (ID) numbers used in the previous study (Monistero et al., 2018). All of them were positive for the gene for α -hemolysis (*hla*) but negative for a gene involved in host cell invasion (*chp*) and 2 antimicrobial resistance genes, 1 responsible for resistance to methicillin (*mecC*) and 1 conferring resistance to erythromycin (*ermA*). The MIC assay demonstrated 100% phenotypical susceptibility to tylosin and amoxicillin-clavulanate. Argentina. All of the 16 isolates from Argentina showed phenotypic intermediate or complete resistance to spiramycin, except 1 (ID 5); 7 (43.8%) isolates were not inhibited by erythromycin, and 5 (31.3%) were also not sensitive to lincomycin. Only 1 isolate (ID 12) was phenotypically resistant to ampicillin and penicillin. The nitrocefin-based method detected 2 (12.5%) β -lactamase-positive isolates (Table 4). The molecular analysis revealed that all strains carried *ermC*, except 1 (ID 2), which was negative for this gene. The *ermC* gene was the only erythromycin-resistance gene found in Argentina, although *blaZ* was detected with a frequency of 18.8% (Table 4). The *hly* gene was detected in 93.8% of the Argentinian strains. Among the IEC genes, the most prevalent was *sea* (56.3%), whereas *sak* was carried by 5 (31.3%) isolates, and none harbored *scn* (Table 4). Brazil. All 15 isolates collected in Brazil showed phenotypic intermediate or complete resistance to spiramycin, except 1 (ID 29). Among the Brazilian isolates, 46.7% were not susceptible to lincomycin, and 13.3% were not inhibited by the range of concentration tested for erythromycin. Out of the 15 isolates analyzed, 3 (20%) were found to be β -lactamase-positive by the nitrocefin-based method, also demonstrating in vitro resistance to ampicillin and penicillin, and 3 (20%) showed resistance to the combination of trimethoprim and sulfamethoxazole (Table 5). The genotypic results showed that 46.7% of the Brazilian strains were positive for *blaZ*, and all were negative for both *mecA* and *erm* genes (Table 5). As reported in Table 5, the gene for β -hemolysin (*hly*) was present in 100% of the Brazilian strains. The majority (53.3%) of them carried *sea*, but none harbored the other IEC genes investigated, *scn* and *sak*. Germany. In the MIC assay, 94.1% of German isolates were phenotypically resistant to spiramycin. Out of 17 strains analyzed, 6 (35.3%) showed in vitro resistance to erythromycin and 5 (29.4%) to lincomycin. One isolate (ID 53) was also resistant to ampicillin, oxacillin, penicillin, and the 3 cephalosporins tested (cefazolin, cefoperazone, and cefquinome); this isolate was the only one detected by the nitrocefin-based method. Another single German isolate (5.9%) was classified as having intermediate resistance to cefoperazone, and another 2 (11.8%) were classified as resistant to sulfamethoxazole/trimethoprim (Table 6). As shown in Table 6, 47.1% of the German strains were potentially resistant to penicillin, harboring *blaZ*, whereas the *erm* genes were less prevalent, with 35.3% of the strains positive for *ermB* but none for *ermC*. The single strain phenotypically resistant to 9 different antimicrobials, including methicillin, was the only one (6.9%) positive for *mecA*. Most (64.7%) of the strains isolated from Germany were positive for *hly*. The result related to the presence of the IEC genes indicated that 15 (88.2%) strains carried *sea*, but none possessed the virulence factors associated with suppressing innate immunity (*scn* and *sak*; Table 6). Italy. The results of antimicrobial susceptibility testing (Table 7) showed that more than a half (58.8%) of the isolates collected in Italy were not inhibited by spiramycin or penicillin or both. Out of 10 penicillin-resistant isolates, 9 (52.9%) also showed resistance to ampicillin, and 9 revealed phenotypic β -lactamase activity. One other isolate was detected by the nitrocefin-based method, for a total of 10 (58.8%) β -lactamase-positive isolates with this test. Besides penicillin and ampicillin, 1 isolate (ID 77) was not susceptible to the other 5 drugs (spiramycin, cefoperazone, enrofloxacin, oxacillin, and lincomycin). Two (11.8%) Italian isolates were considered resistant to gentamycin, and 1 (5.9%) also showed in vitro resistance to kanamycin. Only 1 isolate (ID 79) was classified as having intermediate resistance to erythromycin. Of 17 Italian strains, 14 (82.4%) were potentially penicillin-resistant, carrying *blaZ*, and 5 strains (29.4%) also harbored *ermC*. A single strain (5.9%) was positive for *mecA*: this was phenotypically resistant to 7 different antimicrobials, including methicillin, but negative for the *erm* genes (Table 7). Table 7 shows that 94.1% of the strains isolated from Italy carried *hly*; the *sea* gene was detected in 58.8% of the strains, but only 1 (ID 78)

was also positive for both *scn* and *sak* genes. United States (New York State). All American isolates, with 1 exception (ID 97), exhibited resistance to spiramycin. From these spiramycin-resistant isolates, 1 (ID 90) was classified as having intermediate resistance to erythromycin, 1 (ID 82) as having intermediate resistance to rifampicin, and 1 (ID 88) as resistant to lincomycin (Table 8). Among the antimicrobial resistance genes investigated, *blaZ* had a prevalence of 41.2%, and *erm* genes were not identified (Table 8). By contrast, the *hlb* gene was found to be quite diffused (88.2%); *sea* was carried by 52.9%, and *scn* and *sak* were not found (Table 8). South Africa. Among South African isolates, the highest rate of intermediate or complete resistance was found for spiramycin (100%), followed by erythromycin (36.4%). Of 11 isolates analyzed, 3 (27.3%) were phenotypically resistant to penicillin and ampicillin, but only 1 (ID 103) showed phenotypic β -lactamase activity; a second isolate (ID 108) was detected by the nitrocefin-based method, for a total of 2 (18.2%) β -lactamase-positive isolates. Only 1 isolate (ID 100) was classified as having intermediate resistance to lincomycin (Table 9). Of the 6 antimicrobial-resistance genes tested, *blaZ* and *ermB* were detected in the African strains with the same frequency (36.4%; Table 9). Of 11 South African strains analyzed, results (Table 9) showed that 7 (63.6%) carried the gene for β -hemolysin (*hlb*). Among the IEC genes, *sak* and *sea* were detected in 100% and 90.9% of the strains, respectively; 1 (ID 103) of them was also positive for *scn*.

Association Between Phenotypic Resistance and Resistance Genes

The phenotypic results showed that most (93.6%) of the isolates had intermediate resistance or complete resistance to at least 1 of the 16 antimicrobial agents tested. Analyzing the resistance to multiple classes of antimicrobials, 57.0% of isolates were resistant or intermediate to 1 class of antimicrobials, 25.8% to 2 different classes, 8.6% to 3 different classes, and 2.2% (the 2 MRSA isolates) to more than 3. Table 10 reports all the raw MIC values and the MIC₉₀ of the isolates for each antimicrobial tested. The MIC₉₀ of all antimicrobials tested was lower than the resistance breakpoint, except for penicillin, ampicillin, spiramycin, and tylosin. The MIC assay (Table 10) revealed that 50 (53.8%) isolates were not inhibited by the range of concentrations tested for spiramycin, which was the antimicrobial with the highest rate of resistance. Of 93 isolates, 21 (22.6%) were classified as having intermediate resistance or resistance to erythromycin, 20 (21.5%) to lincomycin, 18 (19.4%) to penicillin, and 17 (18.3%) to ampicillin. The nitrocefin-based method detected a total of 18 (19.4%) isolates producing β -lactamase: 15 of these were also phenotypically resistant to penicillin, and 3 showed susceptibility to this drug. In estimating the occurrence of genes responsible for antibiotic resistance using PCR analysis, *blaZ* had the highest frequency (46.2%). Additionally, we investigated the presence of *erm* genes and *mec* genes that can confer resistance to erythromycin and methicillin, respectively. The genotypic results (Figure 1) showed that the resistance rate to erythromycin was 32.3%, and the most frequently detected erythromycin-resistance gene was *ermC* (21.5%), followed by *ermB* (10.8%). The prevalence of methicillin-resistant *S. aureus* strains was low among the isolates analyzed, as only 2 (2.2%) strains harbored *mecA*.

Figure 2 shows the association between the occurrence of genes conferring antibiotic resistance (x-axis) and laboratory-tested phenotypic resistance to antimicrobials (y-axis). The association was calculated as the sum of co-occurrences of genetic and phenotypic resistance to antibiotics, normalized over sample size (Buzdydowski, 2015). The molecular detection of the antibiotic-resistance genes was not always directly proportional to the phenotypic expression of these genes (Figure 2). The gene responsible for resistance to penicillin (*blaZ*) was the most prevalent (46.2%), but only 19.4% of the strains analyzed demonstrated phenotypic resistance to this drug; the same percentage (19.4%) of isolates were reported to be resistant due to a positive nitrocefin test result. All isolates that demonstrated phenotypic resistance to penicillin or β -lactamase activity carried the *blaZ* gene. In addition, 32.3% of the isolates were positive for *erm* genes, but the phenotypic results showed that 21 (22.6%) of the 93 strains analyzed were resistant (5.4%) or had intermediate resistance (17.2%) to

erythromycin; 10 (10.8%) of the intermediate erythromycin-resistant strains were negative for *ermB* or *ermC*. The 2 phenotypically oxacillin-resistant strains were the only ones that harbored *mecA*. Figure 3 shows the comparison of penicillin MIC distribution and frequency of *blaZ*-positive and *blaZ*-negative isolates. The distribution of *blaZ*-positive MIC is scattered along the dilution range, without bimodal distribution and with most of the isolates (23) having the lower MIC. The *blaZ*-negative isolates are gathered in the last 2 MIC dilutions with a clear unimodal distribution. Figure 3 also displays the comparison of erythromycin MIC distribution and frequency of *erm*-positive and *erm*-negative isolates. In this case, *erm*-positive isolates show a bimodal distribution, having as cutoff the resistance breakpoint, whereas *erm*-negative isolates are distributed only behind the resistance cutoff, with the major frequency at 0.5 µg/mL.

DISCUSSION

Of the 93 *S. aureus* strains analyzed, only 2 European isolates harbored *mecA*. None were positive for *mecC*, a recently identified *mecA* homolog detected in humans and in a wide range of domestic and wild animals from different European countries (Schlotter et al., 2014). Our results confirmed the low prevalence of MRSA among *S. aureus* strains collected from bovine mastitis samples (Hendriksen et al., 2008; Silva et al., 2013; da Costa Krewer et al., 2015; Luini et al., 2015). The β-lactam antibiotics have been largely used to treat *S. aureus* mastitis for several decades, but their efficiency is reduced by bacterial β-lactamases. The *blaZ* gene, which encodes β-lactamase and confers resistance to penicillin (Olsen et al., 2006), was the most frequently detected resistance gene, found in 43 strains. Of these, 21, including the 2 MRSA isolates, were reported to be phenotypically resistant to penicillin based on MIC or nitrocefin-based test results. Therefore, the remaining 50% of the *blaZ*-positive isolates were phenotypically susceptible to penicillin, in agreement with previous results reported by Ruegg and collaborators (2015). Haveri et al. (2005) suggested that the occurrence of isolates with phenotypic resistance to a certain antibiotic might not always be proportional to the presence of the corresponding resistance gene. Considering the isolates susceptible to penicillin but positive for *blaZ* as potentially resistant (Haveri et al., 2005), our results confirmed that resistance to penicillin was the most frequently observed resistance mechanism, although with a lower prevalence than the over 60% reported by Malinowski and collaborators (2002, 2008). On the other hand, looking at the comparison of penicillin MIC distribution and the frequency of *blaZ*-positive and *blaZ*-negative isolates, most of the isolates had the lowest MIC. This discrepancy between phenotypic and genotypic results may demonstrate that the detection of genes does not necessarily implicate their expression; indeed, the percentage of isolates phenotypically resistant to penicillin was in agreement with previous results (Ruegg et al., 2015), reporting that the resistance rate to this drug has declined (Makovec and Ruegg, 2003), even with differences among geographical areas. Previous studies demonstrated that the occurrence of phenotypically penicillin-resistant *S. aureus* strains was higher in Argentina (40%; Gentilini et al., 2000) than in Germany (17%; Tenhagen et al., 2006) or in the United States (10%; Anderson et al., 2006). Accordingly, we found higher resistance rates in Argentina and Germany compared with New York State, but the rates were overall lower (12.5% in Argentina, 5.9% in Germany, and 0% in New York State). Of 18 phenotypically penicillin-resistant isolates, 17 were not inhibited even by the highest concentration of ampicillin tested, in accordance with previous studies (El Behiry et al., 2012; Jagielski et al., 2014). This outcome could be explained by the presence of *blaZ* in all these strains, because penicillin, as well as ampicillin, is inactivated by the β-lactamase encoded by *blaZ*. Among them, 3 were negative for the β-lactamase test; this discrepancy could be due to the lower sensitivity of the nitrocefin test compared with MIC assay and PCR analysis for the *blaZ* gene (Ferreira et al., 2017). All 93 isolates analyzed in this study were susceptible to the association of amoxicillin and clavulanate, with a very low MIC₉₀ (0.5 µg/mL). Considering the uncertainties connected to laboratory methods for detection of β-lactamase-producing *S. aureus* strains, the use of amoxicillin and clavulanate could be

recommended when only phenotypic methods are available to test resistance to penicillin, given also its demonstrated efficiency in mastitis therapy (Güler et al., 2005). In addition to the genes responsible for resistance to β -lactams, we investigated the presence of the genes encoding resistance to erythromycin. We detected *erm* genes in 30 of the 93 isolates analyzed and found that *ermC* was the most prevalent gene, similar to the results of Aarestrup and Schwarz (2006) and Sawant et al. (2009). The phenotypic results showed that the MRSA strain collected in Germany was positive for *ermB* and was also classified as phenotypically erythromycin-resistant, whereas the other MRSA isolate from Italy was negative for both *erm* genes tested and was susceptible to erythromycin. Of 30 isolates positive for *erm* genes, 5 were classified as having complete resistance and 6 as having intermediate resistance to erythromycin. The susceptibility of the remaining 19 isolates could be due to lack of expression of methylases encoded by *erm* genes, in agreement with previous studies (Fluit et al., 2001). The other 10 isolates negative for *erm* genes showed intermediate resistance to erythromycin, but they were very close to the CLSI breakpoints; therefore, we cannot discount the possibility that some of them could be considered susceptible. Surprisingly, among the macrolides tested, we found a high number of isolates resistant to spiramycin but susceptible to erythromycin, when the genes responsible for resistance to erythromycin usually also confer resistance to other macrolides. The possibility of an uncorrected resistance breakpoint should be taken into account, and the MIC distribution could be helpful to analyze the data. Spiramycin MIC results (Table 10) show a bimodal distribution, with an epidemiological cutoff at 4 $\mu\text{g}/100\text{ mL}$, which seems to split the isolates into 2 different phenotypical populations and which corresponds to the resistance breakpoint. A greater number of isolates and dilution points in the area of resistance would be needed to assess the accuracy of the breakpoint. Therefore, possible bias due to an incorrect resistance breakpoint cannot be excluded, even if the epidemiological cutoff is consistent with the breakpoint for this set of data. Another possible explanation of this phenomenon could be the presence among the isolates of other genes encoding resistance to macrolides that have not been tested in this study. The emergence of macrolide-resistance genes conferring resistance to spiramycin but not to erythromycin has been described in *Streptococcus uberis* (Achard et al., 2008). The cephalosporins, usually classed into different generations based on their antimicrobial spectrum, are often used to treat mastitis in dairy ruminants (Moroni et al., 2005). Globally, there are intramammary formulations of first-generation cephalosporins (cefazolin, cephalexin, cephalotin, cephalonium, and cephapirin), second-generation (cefuroxime), third-generation (cephoperazone and ceftiofur), and fourth-generation (cefquinome; Moroni et al., 2005; Oliveira and Ruegg, 2014; Ruegg et al., 2015). We tested cefazolin as a first-generation cephalosporin, and cephaloperazone and cefquinome as third- and fourth-generations, respectively. These last 2 antimicrobials, classified by the World Health Organization (WHO, 2019) as highestpriority critically important antibiotics (HPCIA), were tested in this study because they were included in the MIC plates used for routine testing. It is important to highlight that the use of third- and fourth-generation cephalosporins should be limited only to gram-negative bacteria that show resistance to antibiotics different from HPCIA (WHO, 2017). The use of other drugs, such as first-generation cephalosporins or amoxicillin-clavulanate, should be preferred to these cephalosporins for the treatment of staphylococcal mastitis. Results showed that the 2 MRSA isolates both displayed resistance to cephaloperazone (MIC 8 $\mu\text{g}/\text{mL}$). Moreover, the MRSA strain isolated in Germany had a MIC of 4 $\mu\text{g}/\text{mL}$, classified as intermediate, to cefazolin and cefquinome, whereas that isolated in Italy had a MIC of 2 $\mu\text{g}/\text{mL}$, classified as susceptible, to both drugs. The 2 MRSA isolates were resistant to oxacillin with a MIC value $>4\ \mu\text{g}/\text{mL}$, outside the dilution range. These data highlight that only oxacillin or ceftiofur should be used to phenotypically assess the presence of MRSA, confirming the detection of the *mecA* gene, as advised by CLSI (2013). However, bovine mastitis caused by *S. aureus* strains positive for the *mecA* gene and treated by administration of cephalosporins show clinical outcomes with low probability of cure (Pol and Ruegg, 2007; Oliveira and Ruegg, 2014; Krömker and Leimbach, 2017). For this reason, antibiotic treatment decisions should be based not only on the diagnosis of the mastitis causative agents

obtained through microbiological and sensitivity test results but also on the identification of animals with high healing prospects (Krömker and Leimbach, 2017). The MIC₉₀ was lower than the resistance breakpoint for the majority of the antimicrobials tested. This outcome was expected, in agreement with previous studies (Gentilini et al., 2000; Ruegg et al., 2015). Therefore, for many antimicrobials, we selected a dilution range wider in the lower side and narrow in the upper part, to possibly detect the presence of bimodal distribution also in the susceptibility dilution range. This reduced the possibility of investigating the extent of the resistance level for some antimicrobials, such as lincomycin, spiramycin, and tylosin. Analysis of the virulence profiles of the 93 *S. aureus* strains revealed that the 2 adhesion factors Hla and Hlb, also involved in host invasion (Moroni et al., 2011), were the most frequently detected. In fact, the genes for α - and β -hemolysins were found to be widely distributed in all the 6 countries analyzed, in agreement with Aarestrup et al. (1999). All strains were positive for hla (100%), and 79 (84.9%) also carried hlb. The gene for α -toxin is present in essentially all *S. aureus* strains (Monecke et al., 2014), including strains isolated from humans, whereas the β -toxin gene, whose activity may be important in the pathogenesis of mastitis, is more frequent in bovine rather than human isolates (Larsen et al., 2002). We also investigated the occurrence of the IEC genes that play an important role in human medicine (Baptistão et al., 2016), especially in infections caused by MRSA (McCarthy and Lindsay, 2013). This cluster comprises the staphylococcal complement inhibitor gene (scn) and the chemotaxis inhibitory protein (chp), which are located on an 8-kb region at the conserved 3' end of β -hemolysin (hly)-converting bacteriophages (β C- ϕ s). The region at the conserved 3' end encodes the genes sak, sea, or sep (van Wamel et al., 2006). Seven different IEC types (A to G) were previously identified, based on the occurrence of sea, sep, sak, chp, and scn genes, and type B (sak-chp-scn) was the most prevalent (van Wamel et al., 2006). The presence of this cluster in large animals was previously investigated in MRSA and methicillin-sensitive *S. aureus* (MSSA) isolates from different kinds of infections in pigs and horses as well as in humans with occupational exposure to pigs and horses (Cuny et al., 2015). Cuny and collaborators (2015) detected the IEC genes only in MRSA from horse clinics and the colonization of veterinary personal, probably for a re-adaptation to humans. Acquisition of the IEC is probably one of the first steps in the process of adaptation to animals and including loss or acquisition of genetic elements (Schijffelen et al., 2010). In this context, we investigated the occurrence of the IEC genes in *S. aureus* isolates from bovine intramammary infection. Our results showed that neither strain of MRSA found in our study carried these genes: the one from Germany was negative for all of them, whereas that from Italy carried only the gene encoding for enterotoxin A. However, the IEC type D was detected in 1 Italian and 1 South African MSSA, carrying scn, sak, and sea. This cluster type has been described as quite common in human MRSA (van Wamel et al., 2006). The gene chp was overall absent, but sak was present in 31.3% of Argentinian and 100% of South African strains. Our findings are in accordance with a recent paper (Magro et al., 2017) reporting that only bovine isolates were devoid of such prophage, probably because the untruncated hly is necessary in ungulates for the different structure of erythrocyte membranes. In contrast to our results, the IEC genes were reported to be quite frequent in a recent Tunisian study on *S. aureus* strains collected from cow and ewe milk: IEC type B was predominant (Khemiri et al., 2019). The sea gene was carried, on average, by half of the isolates from each country, with the exception of Germany and South Africa, where the prevalence of this gene was 88.2% and 90.1%, respectively.

CONCLUSIONS

Although it is not straightforward to generalize to the global dairy population, given the limited size and the non-probability convenience sampling scheme of this study, our results strengthen the knowledge of the virulence and antibiotic-resistance patterns of *S. aureus* strains in dairy cows. Few specific genes were frequently detected in the strains analyzed, suggesting that they could be related to the ability of *S. aureus* to colonize the host. The bla_Z gene was identified in most of the isolates

analyzed, even though the detection of this gene, as well as of *erm* genes, did not correspond with the relative occurrence of phenotypic resistance; further research will be necessary to validate phenotypic susceptibility testing and genotypic testing. Notwithstanding the ongoing alert on methicillin-resistant *S. aureus* strains, only 2 MRSA isolates were identified in this study; all other isolates were susceptible to oxacillin, and the majority were also susceptible to most antimicrobials tested. Therefore, the presence of highly multidrug-resistant isolates was low, and the emergence of widespread *S. aureus* multidrug resistance is limited to MRSA, in agreement with the previously mentioned works. The results of the present work show that the prevalence of antimicrobial-resistant *S. aureus* strains vary depending on country and herd, but collection of more comprehensive data through collaboration with a greater number of countries can provide further information on the spreading of antibiotic resistance; these findings could be used for further studies or metaanalysis on combined data sets. To date, the results suggest that it is necessary to maintain the described antimicrobial resistance trends, making antibiotic treatment decisions based on rapid diagnostic and resistance tests, and to keep an adequate level of surveillance on the presence of MRSA in dairy cattle, to avoid the spreading of these strains in dairy cattle populations and beyond.

ACKNOWLEDGMENTS

The authors acknowledge Belinda Gross and Janie C. Lee (Animal Health Diagnostic Center, Cornell University, Ithaca, NY) for their valuable revision of the English text. The authors have not stated any conflicts of interest.

REFERENCES

- Aarestrup, F. M., H. D. Larsen, N. H. Eriksen, C. S. Elsberg, and N. E. Jensen. 1999. Frequency of α - and β -haemolysin in *Staphylococcus aureus* of bovine and human origin. A comparison between pheno- and genotype and variation in phenotypic expression. *APMIS* 107:425–430. <https://doi.org/10.1111/j.1699-0463.1999.tb01576.x>.
- Aarestrup, F. M., and S. Schwarz. 2006. Antimicrobial resistance in staphylococci and streptococci of animal origin. Pages 187–212 in *Antimicrobial Resistance in Bacteria of Animal Origin*. F. M. Aarestrup, ed. ASM Press, Washington, DC.
- Achard, A., V. Guérin-Faubleé, V. Pichereau, C. Villers, and R. Leclercq. 2008. Emergence of macrolide resistance gene *mph(B)* in *Streptococcus uberis* and cooperative effects with *rdmC*-like gene. *Antimicrob. Agents Chemother.* 52:2767–2770. <https://doi.org/10.1128/AAC.00481-08>.
- Anderson, K. L., R. L. Lyman, S. M. Bodeis-Jones, and D. G. White. 2006. Genetic diversity and antimicrobial susceptibility profiles among mastitis-causing *Staphylococcus aureus* isolated from bovine milk samples. *Am. J. Vet. Res.* 67:1185–1191. <https://doi.org/10.2460/ajvr.67.7.1185>.
- Baptistão, L. G., N. C. C. Silva, E. C. R. Bonsaglia, B. F. Rossi, I. G. Castilho, A. Fernandes Junior., and V. L. M. Rall. 2016. Presence of immune evasion cluster and molecular typing of methicillin-susceptible *Staphylococcus aureus* isolated from food handlers. *J. Food Prot.* 79:682–686. <https://doi.org/10.4315/0362-028X.JFP-15-401>.
- Barkema, H. W., Y. H. Schukken, and R. N. Zadoks. 2006. Invited review: The role of cow, pathogen, and treatment regimen in the therapeutic success of bovine *Staphylococcus aureus* mastitis. *J. Dairy Sci.* 89:1877–1895. [https://doi.org/10.3168/jds.S0022-0302\(06\)72256-1](https://doi.org/10.3168/jds.S0022-0302(06)72256-1).
- Berube, B. J., and J. Bubeck-Wardenburg. 2013. *Staphylococcus aureus* α -toxin: Nearly a century of intrigue. *Toxins (Basel)* 5:1140–1166. <https://doi.org/10.3390/toxins5061140>.
- Buzydowski, Jan W. 2015. Co-occurrence analysis as a framework for data mining. *J. Technol. Res.* 6.
- Clarke, S. R., and S. J. Foster. 2006. Surface adhesins of *Staphylococcus aureus*. *Adv. Microb. Physiol.* 51:187–224. [https://doi.org/10.1016/S0065-2911\(06\)51004-5](https://doi.org/10.1016/S0065-2911(06)51004-5).
- CLSI. 2013. Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated from Animals: Approved Standard. 4th ed. CLSI document Vet 01-A4. Clinical and Laboratory Standards Institute, Wayne, PA.

CLSI. 2018. Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated from Animals. 4th ed. CLSI supplement VET 08. Clinical and Laboratory Standards Institute, Wayne, PA. Cockerill, F. R. III. 1999. Genetic methods for assessing antimicrobial resistance. *Antimicrob. Agents Chemother.* 43:199–212. <https://doi.org/10.1128/AAC.43.2.199>. Cookson, B. 1997. *Staphylococcus aureus*. Page 109 in *Principles of Clinical Bacteriology*. M. Emmerson, C. Kibbler, and P. Hawkey, ed. John Wiley, Oxford, UK. Cremonesi, P., B. Castiglioni, G. Malferrari, I. Biunno, C. Vimercati, P. Moroni, S. Morandi, and M. Luzzana. 2006. Technical note: Improved method for rapid DNA extraction of mastitis pathogens directly from milk. *J. Dairy Sci.* 89:163–169. [https://doi.org/10.3168/jds.S0022-0302\(06\)72080-X](https://doi.org/10.3168/jds.S0022-0302(06)72080-X). Cremonesi, P., M. Luzzana, M. Brasca, S. Morandi, R. Lodi, C. Vimercati, D. Agnellini, G. Caramenti, P. Moroni, and B. Castiglioni. 2005. Development of a multiplex PCR assay for the identification of *Staphylococcus aureus* enterotoxigenic strains isolated from milk and dairy products. *Mol. Cell. Probes* 19:299–305. <https://doi.org/10.1016/j.mcp.2005.03.002>. Cuny, C., M. Abdelbary, F. Layer, G. Werner, and W. Witte. 2015. Prevalence of the immune evasion gene cluster in *Staphylococcus aureus* CC398. *Vet. Microbiol.* 177:219–223. <https://doi.org/10.1016/j.vetmic.2015.02.031>. da Costa Krewer, C., E. Santos Amanso, G. Veneroni Gouveia, R. de Lima Souza, M. M. da Costa, and R. Aparecido Mota. 2015. Resistance to antimicrobials and biofilm formation in *Staphylococcus* spp. isolated from bovine mastitis in the Northeast of Brazil. *Trop. Anim. Health Prod.* 47:511–518. <https://doi.org/10.1007/s11250-014-0752-9>. El Behiry, A., G. Schlenker, I. Szabo, and U. Roesler. 2012. In vitro susceptibility of *Staphylococcus aureus* strains isolated from cows with subclinical mastitis to different antimicrobial agents. *J. Vet. Sci.* 13:153–161. <https://doi.org/10.4142/jvs.2012.13.2.153>. Ferreira, A. M., K. B. Martins, V. R. Silva, A. L. Mondelli, and M. L. Cunha. 2017. Correlation of phenotypic tests with the presence of the blaZ gene for detection of beta-lactamase. *Braz. J. Microbiol.* 48:159–166. <https://doi.org/10.1016/j.bjm.2016.10.011>. Feßler, A. T., H. Kaspar, C. J. Lindeman, M. R. Stegemann, T. Peters, J. Mankertz, J. L. Watts, and S. Schwarz. 2012. A proposal of interpretive criteria for cefoperazone applicable to bovine mastitis pathogens. *Vet. Microbiol.* 157:226–231. <https://doi.org/10.1016/j.vetmic.2011.11.032>. Fluit, A. C., M. R. Visser, and F. J. Schmitz. 2001. Molecular detection of antimicrobial resistance. *Clin. Microbiol. Rev.* 14:836–871. <https://doi.org/10.1128/CMR.14.4.836-871.2001>. Fournier, C., P. Kuhnert, J. Frey, R. Miserez, M. Kirchhofer, T. Kaufmann, A. Steiner, and H. U. Graber. 2008. Bovine *Staphylococcus aureus*: Association of virulence genes, genotypes and clinical outcome. *Res. Vet. Sci.* 85:439–448. <https://doi.org/10.1016/j.rvsc.2008.01.010>. Gao, J., M. Ferreri, F. Yu, X. Liu, L. Chen, J. Su, and B. Han. 2012. Molecular types and antibiotic resistance of *Staphylococcus aureus* isolates from bovine mastitis in a single herd in China. *Vet. J.* 192:550–552. <https://doi.org/10.1016/j.tvjl.2011.08.030>. Gatermann, S. G., T. Koschinski, and S. Friedrich. 2007. Distribution and expression of macrolide resistance genes in coagulase-negative staphylococci. *Clin. Microbiol. Infect.* 13:777–781. <https://doi.org/10.1111/j.1469-0691.2007.01749.x>. Gentilini, E., G. Denamiel, P. Llorente, S. Godaly, M. Rebuelto, and O. DeGregorio. 2000. Antimicrobial susceptibility of *Staphylococcus aureus* isolated from bovine mastitis in Argentina. *J. Dairy Sci.* 83:1224–1227. [https://doi.org/10.3168/jds.S0022-0302\(00\)74988-5](https://doi.org/10.3168/jds.S0022-0302(00)74988-5). Güler, L., U. Ok, K. Gündüz, Y. Gülcü, and H. H. Hadimli. 2005. Antimicrobial susceptibility and coagulase gene typing of *Staphylococcus aureus* isolated from bovine clinical mastitis cases in Turkey. *J. Dairy Sci.* 88:3149–3154. [https://doi.org/10.3168/jds.S0022-0302\(05\)72998-2](https://doi.org/10.3168/jds.S0022-0302(05)72998-2). Gussmann, M., W. Steeneveld, C. Kirkeby, H. Hogeveen, M. Farre, and T. Halasa. 2019. Economic and epidemiological impact of different intervention strategies for subclinical and clinical mastitis. *Prev. Vet. Med.* 166:78–85. <https://doi.org/10.1016/j.prevetmed.2019.03.001>. Haveri, M., S. Suominen, L. Rantala, T. Honkanen-Buzalski, and S. Pyorala. 2005. Comparison of phenotypic and genotypic detection of penicillin G resistance of *Staphylococcus aureus* isolated from bovine intramammary infection. *Vet. Microbiol.* 106:97–102. <https://doi.org/10.1016/j.vetmic.2004.12.015>. Heikkilä, A. M., E. Liski, S. Pyörälä, and S. Taponen. 2018. Pathogen-specific production losses in

bovine mastitis. *J. Dairy Sci.* 101:9493–9504. <https://doi.org/10.3168/jds.2018-14824>. Hendriksen, R. S., D. J. Mevius, A. Schroeter, C. Teale, D. Meunier, P. Butaye, A. Franco, A. Utinane, A. Amado, M. Moreno, C. Greko, K. Stärk, C. Berghold, A. L. Myllyniemi, D. Wasyl, M. Sunde, and F. M. Aarestrup. 2008. Prevalence of antimicrobial resistance among bacterial pathogens isolated from cattle in different European countries: 2002–2004. *Acta Vet. Scand.* 50:28. <https://doi.org/10.1186/1751-0147-50-28>. Jagielski, T., E. Puacz, A. Lisowski, P. Siedlecki, W. Dudziak, J. Międzobrodzki, and H. Krukowski. 2014. Antimicrobial susceptibility profiling and genotyping of *Staphylococcus aureus* isolates from bovine mastitis in Poland. *J. Dairy Sci.* 97:6122–6128. <https://doi.org/10.3168/jds.2014-8321>. Jarraud, S., C. Mougél, J. Thioulouse, G. Lina, H. Meugnier, F. Forey, X. Nesme, J. Etienne, and F. Vandenesch. 2002. Relationships between *Staphylococcus aureus* genetic background, virulence factors, agr groups (alleles), and human disease. *Infect. Immun.* 70:631–641. <https://doi.org/10.1128/iai.70.2.631-641.2002>. Jensen, L. B., N. Frimodt-Møller, and F. M. Aarestrup. 1999. Presence of erm gene classes in 271 gram-positive bacteria of animal and human origin in Denmark. *FEMS Microbiol. Lett.* 170:151–158. <https://doi.org/10.1111/j.1574-6968.1999.tb13368.x>. Khemiri, M., M. S. Abbassi, H. Elghaieb, M. Zouari, R. Dhahri, C. Pomba, and S. Hammami. 2019. High occurrence of enterotoxigenic isolates and low antibiotic resistance rates of *Staphylococcus aureus* isolated from raw milk from cows and ewes. *Lett. Appl. Microbiol.* 68:573–579. <https://doi.org/10.1111/lam.13152>. Krömker, V., and S. Leimbach. 2017. Mastitis treatment-reduction in antibiotic usage in dairy cows. *Reprod. Domest. Anim.* 52 (Suppl. 3):21–29. <https://doi.org/10.1111/rda.13032>. Lang, I., M. Rose, E. Thomas, and E. Zschiesche. 2002. A field study of cefquinome for the treatment of pigs with respiratory disease. *Rev. Med. Vet.* 153:575–580. Larsen, H. D., F. M. Aarestrup, and N. E. Jensen. 2002. Geographical variation in the presence of genes encoding superantigenic exotoxins and β -hemolysin among *Staphylococcus aureus* isolated from bovine mastitis in Europe and USA. *Vet. Microbiol.* 85:61–67. [https://doi.org/10.1016/s0378-1135\(01\)00478-3](https://doi.org/10.1016/s0378-1135(01)00478-3). Luini, M., P. Cremonesi, G. Magro, V. Bianchini, G. Minozzi, B. Castiglioni, and R. Piccinini. 2015. Methicillin-resistant *Staphylococcus aureus* (MRSA) is associated with low within-herd prevalence of intra-mammary infections in dairy cows: Genotyping of isolates. *Vet. Microbiol.* 178:270–274. <https://doi.org/10.1016/j.vetmic.2015.05.010>. Magro, G., S. Biffani, G. Minozzi, R. Ehricht, S. Monecke, M. Luini, and R. Piccinini. 2017. Virulence genes of *S. aureus* from dairy cow mastitis and contagiousness risk. *Toxins (Basel)* 9:195. <https://doi.org/10.3390/toxins9060195>. Makovec, J. A., and P. L. Ruegg. 2003. Antimicrobial resistance of bacteria isolated from dairy cow milk samples submitted for bacterial culture: 8,905 samples (1994–2001). *J. Am. Vet. Med. Assoc.* 222:1582–1589. <https://doi.org/10.2460/javma.2003.222.1582>. Malinowski, E., A. Kłossowska, M. Kaczmarowski, H. Lassa, and K. Kuźma. 2002. Antimicrobial susceptibility of staphylococci isolated from affected with mastitis cows. *Bull. Vet. Inst. Pulawy* 46:289–294. Malinowski, E., H. Lassa, S. Smulski, A. Kłossowska, and M. Kaczmarowski. 2008. Antimicrobial susceptibility of bacteria with mastitis in 2006–2007. *Bull. Vet. Inst. Pulawy* 52:565–572. McCarthy, A. J., and J. A. Lindsay. 2013. *Staphylococcus aureus* innate immune evasion is lineage-specific: A bioinformatics study. *Infect. Genet. Evol.* 19:7–14. <https://doi.org/10.1016/j.meegid.2013.06.012>. McClure, J. A., J. M. Conly, V. Lau, S. Elsayed, T. Louie, W. Hutchins, and K. Zhang. 2006. Novel multiplex PCR assay for detection of the staphylococcal virulence marker Panton-Valentine leukocidin genes and simultaneous discrimination of methicillin-susceptible from -resistant staphylococci. *J. Clin. Microbiol.* 44:1141–1144. <https://doi.org/10.1128/JCM.44.3.1141-1144.2006>. Monecke, S., E. Müller, J. Büchler, B. Stieber, and R. Ehricht. 2014. *Staphylococcus aureus* in vitro secretion of alpha toxin (hla) correlates with the affiliation to the clonal complexes. *PLoS One* 9:e100427. <https://doi.org/10.1371/journal.pone.0100427>. Monistero, V., H. U. Graber, C. Pollera, P. Cremonesi, B. Castiglioni, E. Bottini, A. Ceballos-Marquez, L. Lasso-Rojas, V. Kroemker, N. Wente, I. M. Petzer, C. Santisteban, J. Runyan, M. Veiga Dos Santos, B. G. Alves, R. Piccinini, V. Bronzo, M. S. Abbassi, M. B. Said, and P. Moroni. 2018. *Staphylococcus aureus* isolates from bovine mastitis in eight countries: Genotypes, detection of genes encoding different toxins and other virulence genes. *Toxins (Basel)*

10:247. <https://doi.org/10.3390/toxins10060247>. Moroni, P., G. Pisoni, M. Antonini, R. Villa, P. Boettcher, and S. Carli. 2006. Short communication: Antimicrobial drug susceptibility of *Staphylococcus aureus* from subclinical bovine mastitis in Italy. *J. Dairy Sci.* 89:2973–2976. [https://doi.org/10.3168/jds.S0022-0302\(06\)72569-3](https://doi.org/10.3168/jds.S0022-0302(06)72569-3). Moroni, P., G. Pisoni, P. Cremonesi, and B. Castiglioni. 2011. *Staphylococcus*. Pages 307–317 in *Molecular Detection of Human Bacterial Pathogens*. Dongyou Liu, ed. CRC Press, Boca Raton, FL. Moroni, P., G. Pisoni, C. Vimercati, M. Rinaldi, B. Castiglioni, P. Cremonesi, and P. Boettcher. 2005. Characterization of *Staphylococcus aureus* isolated from chronically infected dairy goats. *J. Dairy Sci.* 88:3500–3509. [https://doi.org/10.3168/jds.S0022-0302\(05\)73035-6](https://doi.org/10.3168/jds.S0022-0302(05)73035-6). Oliveira, L., and P. L. Ruegg. 2014. Treatments of clinical mastitis occurring in cows on 51 large dairy herds in Wisconsin. *J. Dairy Sci.* 97:5426–5436. <https://doi.org/10.3168/jds.2013-7756>. Olsen, J. E., H. Christensen, and F. M. Aarestrup. 2006. Diversity and evolution of blaZ from *Staphylococcus aureus* and coagulase-negative staphylococci. *J. Antimicrob. Chemother.* 57:450–460. <https://doi.org/10.1093/jac/dki492>. Otto, M. 2014. *Staphylococcus aureus* toxins. *Curr. Opin. Microbiol.* 17:32–37. <https://doi.org/10.1016/j.mib.2013.11.004>. Paterson, G. K., E. M. Harrison, and M. A. Holmes. 2014. The emergence of mecC methicillin-resistant *Staphylococcus aureus*. *Trends Microbiol.* 22:42–47. <https://doi.org/10.1016/j.tim.2013.11.003>. Paterson, G. K., A. R. Larsen, A. Robb, G. E. Edwards, T. W. Pennycott, G. Foster, D. Mot, K. Hermans, K. Baert, S. J. Peacock, J. Parkhill, R. N. Zadoks, and M. A. Holmes. 2012. The newly described mecA homologue, mecALGA251, is present in methicillin-resistant *Staphylococcus aureus* isolates from a diverse range of host species. *J. Antimicrob. Chemother.* 67:2809–2813. <https://doi.org/10.1093/jac/dks329>. Pol, M., and P. L. Ruegg. 2007. Relationship between antimicrobial drug usage and antimicrobial susceptibility of gram-positive mastitis pathogens. *J. Dairy Sci.* 90:262–273. [https://doi.org/10.3168/jds.S0022-0302\(07\)72627-9](https://doi.org/10.3168/jds.S0022-0302(07)72627-9). Ruegg, P. L. 2011. Managing mastitis and producing quality milk. Pages 207–232 in *Dairy Production Medicine*. C. A. Risco and P. R. Melendez, ed. John Wiley & Sons, Hoboken, NJ. Ruegg, P. L., L. Oliveira, W. Jin, and O. Okwumabua. 2015. Phenotypic antimicrobial susceptibility and occurrence of selected resistance genes in gram-positive mastitis pathogens isolated from Wisconsin dairy cows. *J. Dairy Sci.* 98:4521–4534. <https://doi.org/10.3168/jds.2014-9137>

Saini, V., J. T. McClure, D. Leger, S. Dufour, A. G. Sheldon, D. T. Scholl, and H. W. Barkema. 2012a. Antimicrobial use on Canadian dairy farms. *J. Dairy Sci.* 95:1209–1221. <https://doi.org/10.3168/jds.2011-4527>. Saini, V., J. T. McClure, D. Léger, G. P. Keefe, D. T. Scholl, D. W. Morck, and H. W. Barkema. 2012b. Antimicrobial resistance profiles of common mastitis pathogens on Canadian dairy farms. *J. Dairy Sci.* 95:4319–4332. <https://doi.org/10.3168/jds.2012-5373>. Sakwinska, O., D. Morisset, J.-Y. Madec, A. Waldvogel, P. Moreillon, and M. Haenni. 2011. Link between genotype and antimicrobial resistance in bovine mastitis-related *Staphylococcus aureus* strains, determined by comparing Swiss and French isolates from the Rhone Valley. *Appl. Environ. Microbiol.* 77:3428–3432. <https://doi.org/10.1128/AEM.02468-10>. Salasia, S. I., Z. Khusnan, C. Lammler, and M. Zschock. 2004. Comparative studies on pheno- and genotypic properties of *Staphylococcus aureus* isolated from bovine subclinical mastitis in central Java in Indonesia and Hesse in Germany. *J. Vet. Sci.* 5:103–109. <https://doi.org/10.4142/jvs.2004.5.2.103>. Sawant, A. A., B. E. Gillespie, and S. P. Oliver. 2009. Antimicrobial susceptibility of coagulase-negative *Staphylococcus* species isolated from bovine milk. *Vet. Microbiol.* 134:73–81. <https://doi.org/10.1016/j.vetmic.2008.09.006>. Schijffelen, M. J., C. H. Boel, J. A. van Strijp, and A. C. Fluit. 2010. Whole genome analysis of a livestock-associated methicillin-resistant *Staphylococcus aureus* ST398 isolate from a case of human endocarditis. *BMC Genomics* 11:376. <https://doi.org/10.1186/1471-2164-11-376>. Schlotter, K., R. Huber-Schlenstedt, A. Gangl, H. Hotzel, S. Monecke, E. Müller, A. Reißig, S. Proft, and R. Ehricht. 2014. Multiple cases of methicillin-resistant CC130 *Staphylococcus aureus* harboring mecC in milk and swab samples from a Bavarian dairy herd. *J. Dairy Sci.* 97:2782–2788. <https://doi.org/10.3168/jds.2013-7378>. Silva, N. C., F. F. Guimarães, M. P. Manzi, P. E. Budri, E. GómezSanz, D. Benito, H. Langoni, V. L. M. Rall, and C.

Torres. 2013. Molecular characterization and clonal diversity of methicillin-susceptible *Staphylococcus aureus* in milk of cows with mastitis in Brazil. *J. Dairy Sci.* 96:6856–6862. <https://doi.org/10.3168/jds.2013-6719>. Simjee, S., J. Amedeo, A. M. Barletta, and A. Pridmore. 2011. Effect of the combination of Tylan 200® & Penicillin G in the treatment of mastitis caused by *Staphylococcus aureus* and/or *Streptococcus uberis*. Page 294 in *Udder Health and Communication*. H. Hogeveen and T. J. G. M. Lam, ed. Wageningen Academic Publishers, Wageningen, the Netherlands. Société française de microbiologie. 2018. Comité de l'antibiogramme de la société française de microbiologie. Groupe de travail antibiogramme vétérinaire. Recommandations vétérinaires 2018. Sol, J., O. C. Sampimon, J. J. Snoep, and Y. H. Schukken. 1997. Factors associated with bacteriological cure during lactation after therapy for subclinical mastitis caused by *Staphylococcus aureus*. *J. Dairy Sci.* 80:2803–2808. [https://doi.org/10.3168/jds.S0022-0302\(97\)76243-X](https://doi.org/10.3168/jds.S0022-0302(97)76243-X). Sung, J. M. L., D. H. Lloyd, and J. A. Lindsay. 2008. *Staphylococcus aureus* host specificity: Comparative genomics of human versus animal isolates by multi-strain microarray. *Microbiology* 154:1949–1959. <https://doi.org/10.1099/mic.0.2007/015289-0>. Sutcliffe, J., T. Grebe, A. Tait-Kamradt, and L. Wondrack. 1996. Detection of erythromycin-resistant determinants by PCR. *Antimicrob. Agents Chemother.* 40:2562–2566. <https://doi.org/10.1128/AAC.40.11.2562>. Tenhagen, B. A., G. Koster, J. Wallmann, and W. Heuwieser. 2006. Prevalence of mastitis pathogens and their resistance against antimicrobial agents in dairy cows in Brandenburg, Germany. *J. Dairy Sci.* 89:2542–2551. [https://doi.org/10.3168/jds.S0022-0302\(06\)72330-X](https://doi.org/10.3168/jds.S0022-0302(06)72330-X). USDA. 2007. Part V: Changes in Dairy Cattle Health and Management Practices in the United States, 1996–2007. National Animal Health Monitoring Service, ed. USDA, Washington, DC. van Wamel, W. J. B., S. H. M. Rooijackers, M. Ruyken, K. P. M. van Kessel, and J. A. G. van Strijp. 2006. The innate immune modulators staphylococcal complement inhibitor and chemotaxis inhibitory protein of *Staphylococcus aureus* are located on β -hemolysin-converting bacteriophages. *J. Bacteriol.* 188:1310–1315. <https://doi.org/10.1128/JB.188.4.1310-1315.2006>. Walker, R. D. 2006. Antimicrobial susceptibility testing methods and interpretation of results. Pages 11–26 in *Antimicrobial Therapy in Veterinary Medicine*. S. Guiguere, J. F. Prescott, J. D. Baggot, R. D. Walker, and P.M. Dowling, ed. Blackwell Publishing, Ames, IA. Wenz, J. R., G. M. Barrington, F. B. Garry, R. P. Dinsmore, and R. J. Callan. 2001. Use of systemic disease signs to assess disease severity in dairy cows with acute coliform mastitis. *J. Am. Vet. Med. Assoc.* 218:567–572. <https://doi.org/10.2460/javma.2001.218.567>. WHO. 2017. WHO guidelines on use of medically important antimicrobials in food-producing animals. Accessed Jan. 15, 2020. https://www.who.int/foodsafety/areas_work/antimicrobial-resistance/cia_guidelines/en/. WHO. 2019. WHO list of critically important antimicrobials (WHO CIA list). Accessed Jan. 15, 2020. <https://www.who.int/foodsafety/publications/antimicrobials-sixth/en/>. Xu, S. X., K. J. Gilmore, P. A. Szabo, J. J. Zeppa, M. L. Baroja, S. M. Haeryfar, and J. K. McCormick. 2014. Superantigens subvert the neutrophil response to promote abscess formation and enhance *Staphylococcus aureus* survival in vivo. *Infect. Immun.* 82:3588–3598. <https://doi.org/10.1128/IAI.02110-14>